Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cara Therapeutics Inc Market Cap
Based on ratings from 4 stock analysts, the Cara Therapeutics Inc stock price is expected to increase by 235.56% in 12 months. This is calculated by using the average 12-month stock price forecast for Cara Therapeutics Inc. The lowest target is $1 and the highest is $1.02. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned CARA 0 buy ratings, 4 hold ratings, and 0 sell ratings. This means that analysts expect Cara Therapeutics Inc to generate similar returns as the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CARA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CARA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Stringer Needham | Hold | Downgrade | Jun 13, 2024 | |
| Oren Livnat HC Wainwright & Co. | Neutral | Downgrade | Jun 13, 2024 | |
| Sumant Kulkarni Canaccord Genuity | Hold | $1 | Downgrade | Jun 13, 2024 |
| Joseph Stringer Needham | Buy | $5 | Reiterates | May 23, 2024 |
| Oren Livnat HC Wainwright & Co. | Buy | $3.6 | Reiterates | May 15, 2024 |
| Joseph Stringer Needham | Buy | $5 | Reiterates | May 14, 2024 |
| Joseph Stringer Needham | Buy | $5 | Reiterates | Apr 10, 2024 |
| Joseph Stringer Needham | Buy | $5 | Reiterates | Mar 28, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $10 | Maintains | Mar 6, 2024 |
| Joseph Stringer Needham | Buy | $5 | Reiterates | Mar 5, 2024 |
| Joseph Stringer Needham | Buy | $5 | Maintains | Jan 22, 2024 |
| Oren Livnat HC Wainwright & Co. | Buy | $2.5 | Maintains | Dec 19, 2023 |
| Joseph Stringer Needham | Buy | $6 | Maintains | Dec 18, 2023 |
| David Amsellem Piper Sandler | Neutral | $1 | Downgrade | Nov 14, 2023 |
| Oren Livnat HC Wainwright & Co. | Buy | $7 | Maintains | Oct 19, 2023 |
| David Amsellem Piper Sandler | Overweight | $12 | Maintains | Aug 8, 2023 |
| Joseph Stringer Needham | Buy | $22 | Reiterates | Aug 8, 2023 |
| Dennis Ding Jefferies | Buy | $18 | Reiterates | Jun 27, 2023 |
| Annabel Samimy Stifel | Buy | $28 | Reiterates | Jun 27, 2023 |
| Joseph Stringer Needham | Buy | $22 | Reiterates | May 16, 2023 |
When did it IPO
2014
Staff Count
55
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Christopher A. Posner
Market Cap
$16.7M
In 2023, CARA generated $21.0M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CARA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 13 Jun 2024
Sentiment - NEGATIVE
Source - Benzinga
Summary - Cara Therapeutics Inc (CARA) shares fell significantly in early trading on Thursday, coinciding with a drop of over 100 points in the Dow Jones Industrial Average.
Why It Matters - Cara Therapeutics' share decline signals potential concerns about the company's performance, impacting investor sentiment and contributing to broader market volatility.
Thu, 13 Jun 2024
Sentiment - NEGATIVE
Source - InvestorPlace
Summary - Cara Therapeutics (NASDAQ: CARA) shares are declining following the release of new data from its Part A KOURAGE-1 clinical trial.
Why It Matters - Cara Therapeutics' stock decline signals potential concerns over clinical trial results, affecting investor confidence and future growth prospects in the biopharmaceutical sector.
Wed, 12 Jun 2024
Sentiment - NEGATIVE
Source - Reuters
Summary - Cara Therapeutics will halt a mid-to-late stage study for a drug targeting itching in a neurological condition, as it showed no significant benefit over placebo.
Why It Matters - Cara Therapeutics halting its study signals potential setbacks in drug development, impacting investor confidence and future revenue prospects, likely leading to stock price volatility.
Wed, 12 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cara Therapeutics will discontinue its clinical program for oral difelikefalin in notalgia paresthetica after it showed no significant benefit over placebo, and will seek strategic alternatives.
Why It Matters - Cara Therapeutics' discontinuation of the difelikefalin clinical program signals a setback in its pipeline, potentially impacting stock performance and investor confidence.
Mon, 13 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Topline efficacy and safety results for the KOURAGE 1 Part A pivotal program on notalgia paresthetica are now anticipated by the end of Q2 2024.
Why It Matters - The delayed efficacy results for the KOURAGE 1 trial could impact stock performance, as positive or negative outcomes will influence investor confidence and future market potential.
Mon, 13 May 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Cara Therapeutics reported a quarterly loss of $0.56 per share, exceeding the Zacks Consensus Estimate of a $0.38 loss, and worsening from a $0.49 loss per share a year prior.
Why It Matters - Cara Therapeutics' larger-than-expected quarterly loss signals potential challenges in profitability, which may affect investor confidence and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
